Comparative study of efficacy and adverse effects profile of telmisartan vs enalapril maleate in patients of essential hypertension and diabetic hypertensives

Jhansivani Ch, Chandrakala Kambar, Shankar Kurli

Abstract


Background: Hypertension is the most common cardiovascular disease and is one of the leading causes of morbidity and mortality. Hypertension when associated with Diabetes mellitus increases this risk. To prevent this, we need appropriate antihypertensive agents with better compliance.  By virtue of selective inhibition of angiotensin II type 1 receptor, telmisartan reduces blood pressure throughout the day with high tolerability.

Methods: A longitudinal and interventional study was undertaken including both male and female patients within the age group of 25-55yrs with clinically diagnosed Essential hypertension and essential hypertension associated with type II diabetes mellitus.  Totally 80 patients were enrolled in this study.  They were divided into 2 groups i.e., Essential hypertension group as A and hypertension associated with diabetes group as B with 40 patients in each group. Again A group was divided into 2 sub-groups (A1 & A2) and B into (B1& B2) with 20 patients in each group. A1and B1 sub groups received Tab. Telmisartan 40mg once a day. A2 and B2 sub groups received tab. Enalapril maleate 5mg once daily. The total period of the study was 3 months.

Results: In this study, both telmisartan and enalapril maleate reduced systolic and diastolic blood pressures in A and B groups at 2 weeks, 6 weeks, and 12 weeks almost equally with no statistical significance. But in terms of adverse effect profile, persistent dry cough and rash was observed more in A2 and B2 group than A1 and B1 subgroups.

Conclusions: Telmisartan is effective, better tolerated than enalapril for the treatment of hypertension.


Keywords


Hypertension, Diabetes mellitus, Telmisartan, Enalapril, Blood pressure, Cough

Full Text:

PDF

References


National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension. 1994 Feb;23(2):145-58.

BHS Clinical guidelines CG34; Management of hypertension in adults in primary care. 2010. Available at: http://www.nice.org.uk/nicemedia/pdf/CG034NICEguideline.pdf. Accessed June 2010.

Libby P, Nathan DM, Abraham K, Brunzell JD. Report of the National Heart, Lung and Blood Institute: National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of DM. Circulation. 2005;111:3489-93.

Zou Z, Xi GL, Yuan HB, Zhu QF, Shi XY. Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials. Journal of Human Hypertension. 2009;23(5):339-49.

Chen JH, Cheng JJ, Chen CY, Chiou HC, Huang TY, Tsai CD, Fu MM, Cherng WJ. Comparison of the efficacy and tolerability of telmisartan 40 mg vs. enalapril 10 mg in the treatment of mild-to-moderate hypertension: a multicentre, double-blind study in Taiwanese patients. Int J Clin Pract Suppl. 2004Dec;(145):29-34.

Amerena J, Pappas S, Ouellet JP, Williams L, O'Shaughnessy D.ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension. J Int Med Res. 2002Nov-Dec;30(6):543-52.

L Alcocer, P Fernandez-Bonetti, E Campos, R Dominguez-Henkel, J J de la Fuente, C Segovia-Ayala Clinical efficacy and safety of telmisartan 80 mg once daily compared with enalapril 20 mg once daily in patients with mild-to-moderate hypertension: results of a multicentre study. Int J Clin Pract Suppl. 2004 Dec;(145):23-8. 15617455 Cit:2.

Lacourcière Y, Neutel JM, Davidai G, Koval S.A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens. 2006 Jan;19(1):104-12.

Smith DH. Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clin Ther. 2002Oct;24(10):1484-501.

Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. 1999 Feb;17(2):293-302.

Laverman G, Ruggenenti P, Remuzzi G. Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics? Curr Hypertens Rep. 2003Oct;5(5):364-7.

Frida Liane Plavnik and Artur Beltrame Ribeiro. A Multicenter, Open-Label Study of the Efficacy and Safety of Telmisartan in Mild to Moderate Hypertensive Patients Arq. Bras. Cardiol. São Paulo. 2002Oct;79(4):339-50.

Laurence L. Brunton, John S. Lazo, Keith L Parker- Goodmann and Gilman-The pharmacological basis of theraupetics. 11th ed. USA: Mc Graw-Hill companies; 2006: 802,808 and 809.

Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000 Sep;36(3):646-61.